دورية أكاديمية
أعرض في EDS

Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.

التفاصيل البيبلوغرافية
العنوان: Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.
المؤلفون: Peat TJ; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA. Electronic address: tpeat@purdue.edu., Gaikwad SM; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Dubois W; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Gyabaah-Kessie N; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Zhang S; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Gorjifard S; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; University of Washington, Seattle, WA, USA., Phyo Z; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Johns Hopkins University, Baltimore, MD, USA., Andres M; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Johns Hopkins University, Baltimore, MD, USA., Hughitt VK; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Simpson RM; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Miller MA; Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA., Girvin AT; Palantir Technologies, Palo Alto, CA, USA., Taylor A; Palantir Technologies, Palo Alto, CA, USA., Williams D; Palantir Technologies, Palo Alto, CA, USA., D'Antonio N; Palantir Technologies, Palo Alto, CA, USA., Zhang Y; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Rajagopalan A; McArdle Research Labs, University of Wisconsin, Madison, WI, USA., Flietner E; McArdle Research Labs, University of Wisconsin, Madison, WI, USA., Wilson K; Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA., Zhang X; Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA., Shinn P; Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA., Klumpp-Thomas C; Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA., McKnight C; Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA., Itkin Z; Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA., Chen L; Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA., Kazandijian D; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Zhang J; McArdle Research Labs, University of Wisconsin, Madison, WI, USA., Michalowski AM; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Simmons JK; Natera, San Carlos, CA, USA., Keats J; Translational Genomics Research Institute, Phoenix, AZ, USA., Thomas CJ; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA., Mock BA; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: mockb@mail.nih.gov.
المصدر: Cancer letters [Cancer Lett] 2023 Aug 01; Vol. 568, pp. 216284. Date of Electronic Publication: 2023 Jun 24.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
أسماء مطبوعة: Publication: Limerick : Elsevier Science Ireland
Original Publication: Amsterdam, Elsevier/North-Holland.
مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/genetics, Humans ; High-Throughput Screening Assays ; Drug Synergism ; Cell Cycle ; Drug Combinations ; Cell Line, Tumor ; Drug Resistance, Neoplasm
مستخلص: Drug resistance and disease progression are common in multiple myeloma (MM) patients, underscoring the need for new therapeutic combinations. A high-throughput drug screen in 47 MM cell lines and in silico Huber robust regression analysis of drug responses revealed 43 potentially synergistic combinations. We hypothesized that effective combinations would reduce MYC expression and enhance p16 activity. Six combinations cooperatively reduced MYC protein, frequently over-expressed in MM and also cooperatively increased p16 expression, frequently downregulated in MM. Synergistic reductions in viability were observed with top combinations in proteasome inhibitor-resistant and sensitive MM cell lines, while sparing fibroblasts. Three combinations significantly prolonged survival in a transplantable Ras-driven allograft model of advanced MM closely recapitulating high-risk/refractory myeloma in humans and reduced viability of ex vivo treated patient cells. Common genetic pathways similarly downregulated by these combinations promoted cell cycle transition, whereas pathways most upregulated were involved in TGFβ/SMAD signaling. These preclinical data identify potentially useful drug combinations for evaluation in drug-resistant MM and reveal potential mechanisms of combined drug sensitivity.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
References: Leukemia. 2011 Jun;25(6):1026-35. (PMID: 21468039)
Cancer Cell. 2007 Aug;12(2):131-44. (PMID: 17692805)
Nat Protoc. 2009;4(1):44-57. (PMID: 19131956)
Mol Cancer Ther. 2022 Apr 1;21(4):502-510. (PMID: 35086951)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2349-54. (PMID: 24469833)
Explor Target Antitumor Ther. 2021;2(1):65-106. (PMID: 36046090)
Genome Biol. 2010;11(10):R106. (PMID: 20979621)
J Clin Exp Hematop. 2018;58(2):61-67. (PMID: 29998977)
Curr Top Microbiol Immunol. 1988;141:125-7. (PMID: 3215046)
Nat Rev Clin Oncol. 2018 Jul;15(7):409-421. (PMID: 29686421)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Bioinformatics. 2015 Sep 1;31(17):2912-4. (PMID: 25964631)
Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700)
J Clin Oncol. 2020 Jul 20;38(21):2380-2389. (PMID: 32442065)
Ann Hematol. 2019 Jan;98(1):1-18. (PMID: 30470875)
Mol Cell Biol. 2001 Jan;21(1):310-8. (PMID: 11113205)
Cell. 2011 Sep 16;146(6):904-17. (PMID: 21889194)
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034. (PMID: 12184808)
Oncoscience. 2017 Aug 1;4(7-8):79-94. (PMID: 28966941)
Clin Cancer Res. 2021 Feb 15;27(4):1019-1028. (PMID: 33203644)
Leukemia. 2018 Jun;32(6):1295-1306. (PMID: 29467490)
Recent Pat Anticancer Drug Discov. 2015;10(2):145-62. (PMID: 25782916)
PLoS Comput Biol. 2017 Jan 13;13(1):e1005308. (PMID: 28085880)
Blood. 2005 Aug 1;106(3):812-7. (PMID: 15855274)
PLoS One. 2010 Nov 15;5(11):e13984. (PMID: 21085593)
Leukemia. 2020 Jan;34(1):322-326. (PMID: 31439946)
Nat Rev Dis Primers. 2017 Jul 20;3:17046. (PMID: 28726797)
Cancer Cell. 2008 Feb;13(2):167-80. (PMID: 18242516)
Blood. 2007 Feb 1;109(3):1228-32. (PMID: 16840723)
Future Oncol. 2017 Jun;13(13):1137-1148. (PMID: 28326839)
J Clin Oncol. 2021 Oct 1;39(28):3171-3181. (PMID: 34357781)
Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
Int J Mol Sci. 2018 Nov 15;19(11):. (PMID: 30445802)
Nat Rev Drug Discov. 2006 Aug;5(8):649-59. (PMID: 16883303)
Cancer Res. 2010 Jan 15;70(2):440-6. (PMID: 20068163)
Mol Cancer Ther. 2010 Aug;9(8):2344-53. (PMID: 20663931)
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2429-34. (PMID: 9482902)
Curr Top Microbiol Immunol. 1988;141:115-24. (PMID: 3215045)
Curr Chem Genomics. 2010 Oct 21;4:57-66. (PMID: 21331310)
J Immunother Cancer. 2020 Jul;8(2):. (PMID: 32661116)
N Engl J Med. 2019 May 2;380(18):1726-1737. (PMID: 31042825)
Blood. 2021 Jan 7;137(1):61-74. (PMID: 32640012)
Blood. 2015 Jan 15;125(3):443-8. (PMID: 25395429)
Pharmacol Rev. 2013 Dec 31;66(1):334-95. (PMID: 24381236)
Sci Rep. 2022 Jun 23;12(1):10616. (PMID: 35739276)
Mol Oncol. 2014 Mar;8(2):261-72. (PMID: 24429254)
Nat Rev Cancer. 2017 Aug;17(8):502-508. (PMID: 28643779)
Genes Dev. 2000 Oct 1;14(19):2501-14. (PMID: 11018017)
Front Cell Dev Biol. 2017 Feb 23;5:10. (PMID: 28280720)
Blood. 2006 Jun 15;107(12):4589-96. (PMID: 16484590)
Exp Hematol. 2003 Apr;31(4):271-82. (PMID: 12691914)
Blood. 2016 Dec 22;128(25):2941-2948. (PMID: 27729323)
Mol Cancer Ther. 2017 Sep;16(9):2008-2021. (PMID: 28522584)
معلومات مُعتمدة: R01 CA152108 United States CA NCI NIH HHS; ZIA BC011065 United States ImNIH Intramural NIH HHS
فهرسة مساهمة: Keywords: Dinaciclib; Entinostat; MYC; Myeloma; p16
المشرفين على المادة: 0 (Drug Combinations)
تواريخ الأحداث: Date Created: 20230625 Date Completed: 20230721 Latest Revision: 20240802
رمز التحديث: 20240802
مُعرف محوري في PubMed: PMC10408729
DOI: 10.1016/j.canlet.2023.216284
PMID: 37356470
قاعدة البيانات: MEDLINE
الوصف
تدمد:1872-7980
DOI:10.1016/j.canlet.2023.216284